JMP Securities Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $3
Promising Potential of Allakos's AK006 Drives Buy Rating Amidst Market Interest in Chronic Spontaneous Urticaria
A Quick Look at Today's Ratings for Allakos(ALLK.US), With a Forecast Between $1 to $7
Cautious Hold Rating for Allakos Amid Uncertain Clinical and Financial Outlook
Piper Sandler Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $7
Barclays Maintains Allakos(ALLK.US) With Sell Rating, Maintains Target Price $1
TD Cowen Maintains Allakos(ALLK.US) With Hold Rating
Allakos (ALLK) Gets a Hold From TD Cowen
Analysts Conflicted on These Healthcare Names: Allakos (ALLK), Edwards Lifesciences (EW) and NewAmsterdam Pharma Company (NAMS)
TD Cowen Maintains Allakos(ALLK.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)
LifeSci Capital Maintains Allakos(ALLK.US) With Hold Rating
JMP Securities Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $3
JMP Securities Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $3
Maintaining Hold on Allakos: Weighing AK006 Promise Against Clinical Setbacks
Allakos's Promising Drug and Financial Health Garner a Buy Rating
TD Cowen Sticks to Its Hold Rating for Allakos (ALLK)
Jefferies Maintains Hold on Allakos, Lowers Price Target to $1
Allakos Analyst Ratings
Allakos Analyst Ratings